Skip to Main Content

Author Details

Meenhard Herlyn
Ellen and Ronald Caplan Cancer Center, The Wistar Institute
1972
648
122
PMIDPaper TitleJournal TitlePublished Year
38066089ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma.Oncogene2024
36054930A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cells.Neuro Oncol2023
3790373520th Anniversary of the Society for Melanoma Research: Celebrating two decades of progress in melanoma research.Pigment Cell Melanoma Res2023
37948180HRS mediates tumor immune evasion by regulating proteostasis-associated interferon pathway activation.Cell Rep2023
37546876Nextflow Pipeline for Visium and H&E Data from Patient-Derived Xenograft Samples.bioRxiv2023
37726985Twenty years of research in melanoma therapy-From "nothing works" to cures: A personal account.Pigment Cell Melanoma Res2023
37639774H3K4me3 remodeling induced acquired resistance through O-GlcNAc transferase.Drug Resist Updat2023
37115855Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors.Cancer Res2023
37343247Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma.Mol Cancer Ther2023
37468627Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells.Nature2023
37377614Targeting Fatty Acid Reprogramming Suppresses CARM1-expressing Ovarian Cancer.Cancer Res Commun2023
37406115Melanoma-intrinsic NR2F6 activity regulates antitumor immunity.Sci Adv2023
37229906Patient-derived melanoma organoid models facilitate the assessment of immunotherapies.EBioMedicine2023
37131684ERK Hyperactivation Serves as a Unified Mechanism of Escape in Intrinsic and Acquired CDK4/6 Inhibitor Resistance in Acral Lentiginous Melanoma.Res Sq2023
36478412Induced pluripotent stem cells reprogramming overcomes technical limitations for highly pigmented adult melanocyte amplification and integration in 3D skin model.Pigment Cell Melanoma Res2023
36711814Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas.bioRxiv2023
36670319Autophagy Paradox: Strategizing Treatment Modality in Melanoma.Curr Treat Options Oncol2023
36633146Targeting the secreted RGDKGE collagen fragment reduces PDâ¿¿L1 by a proteasomeâ¿¿dependent mechanism and inhibits tumor growth.Oncol Rep2023
36331284Targeting UGCG Overcomes Resistance to Lysosomal Autophagy Inhibition.Cancer Discov2023
35296667Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma.Nat Commun2022
35650435Stromal changes in the aged lung induce an emergence from melanoma dormancy.Nature2022
35650266Persister state-directed transitioning and vulnerability in melanoma.Nat Commun2022
35731974Preclinical platforms to study therapeutic efficacy of human γδ T cells.Clin Transl Med2022
35835783HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8<sup>+</sup> T-cell infiltration into tumors.Nat Commun2022
36280724ClampFISH 2.0 enables rapid, scalable amplified RNA detection in situ.Nat Methods2022
36156348MCU controls melanoma progression through a redox-controlled phenotype switch.EMBO Rep2022
35247901Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas.Clin Cancer Res2022
34883044NUMB as a Therapeutic Target for Melanoma.J Invest Dermatol2022
35085484ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression.Dev Cell2022
34996889Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment.Nat Commun2022
33436641Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy.Nat Commun2021
36283004Challenges in the humanized mouse model for cancer: A commentary.J Cancer Biol2021
33545064Melanoma models for the next generation of therapies.Cancer Cell2021
33568355Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling.Cancer Discov2021
33500549Inhibition of endothelin-B receptor signaling synergizes with MAPK pathway inhibitors in BRAF mutated melanoma.Oncogene2021
34937742Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function.J Immunother Cancer2021
34497368TRIM15 and CYLD regulate ERK activation via lysine-63-linked polyubiquitination.Nat Cell Biol2021
34429404Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.Nat Commun2021
34580487Retraction Note: IspH inhibitors kill Gram-negative bacteria and mobilize immune clearance.Nature2021
34518212Protein Signatures of NK Cell-Mediated Melanoma Killing Predict Response to Immunotherapies.Cancer Res2021
34462276Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance.Cancer Res2021
34633384Production of Humanized Mouse via Thymic Renal Capsule Grafting, CD34+ Cells Injection, and Cytokine Delivery.J Vis Exp2021
34654806Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma.Nat Commun2021
34593527A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in Gliomas.Clin Cancer Res2021
33941922Evolution of delayed resistance to immunotherapy in a melanoma responder.Nat Med2021
34304249Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma.Oncogene2021
33361818IspH inhibitors kill Gram-negative bacteria and mobilize immune clearance.Nature2021
33333124ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma.J Invest Dermatol2021
33414132The State of Melanoma: Emergent Challenges and Opportunities.Clin Cancer Res2021
32193336Targeting the cyclin-dependent kinase 5 in metastatic melanoma.Proc Natl Acad Sci U S A2020
  • 1 - 50 of 648

Recommended Authors

Helen T Michael
National Cancer Institute, National Institutes of Health
Career Start Year 2010
Number of shared co-authors 5
Eva P??rez-Guijarro
National Cancer Institute, National Institutes of Health (NIH)
Career Start Year 2009
Number of shared co-authors 15
Steven E Robinson
University of Colorado Anschutz Medical Campus
Career Start Year 2008
Number of shared co-authors 15
M Raza Zaidi
Northwell Health Cancer Institute
Career Start Year 2006
Number of shared co-authors 12
Kristel Kemper
Oncode Institute, The Netherlands Cancer Institute
Career Start Year 2005
Number of shared co-authors 13
Marija Buljan
Sestre milosrdnice University Hospital Centre
Career Start Year 2005
Number of shared co-authors 4
Caroline C Kim
Tufts Medical Center
Career Start Year 2004
Number of shared co-authors 5
Shadmehr Demehri
Massachusetts General Hospital and Harvard Medical School
Career Start Year 2004
Number of shared co-authors 5
Fr??d??rique Deshayes
Universite Paris Cite, CNRS
Career Start Year 2002
Number of shared co-authors 0
Daniela Mihic-Probst
University Hospital Zurich
Career Start Year 2001
Number of shared co-authors 7
Marcory C R F van Dijk
1Rijnstate Hospital
Career Start Year 2001
Number of shared co-authors 0
Daniel Zingg
Netherlands Cancer Institute
Career Start Year 2001
Number of shared co-authors 4
Travis J Hollmann
Memorial Sloan Kettering Cancer Center
Career Start Year 1998
Number of shared co-authors 9
Cindy Sander
UPMC Hillman Cancer Center
Career Start Year 1997
Number of shared co-authors 10
Richard W Joseph
Mayo Clinic Hospital
Career Start Year 1994
Number of shared co-authors 6
Jan Paul Medema
Oncode Institute
Career Start Year 1993
Number of shared co-authors 10
Craig Gedye
Hunter Medical Research Institute, University of Newcastle
Career Start Year 1993
Number of shared co-authors 6
Rene Gonzalez
University of Colorado Anschutz Medical Campus
Career Start Year 1990
Number of shared co-authors 21
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 5
Thomas J Hornyak
University of Maryland School of Medicine
Career Start Year 1989
Number of shared co-authors 2
Roger Chammas
Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina de Sao Paulo
Career Start Year 1989
Number of shared co-authors 1
Daniel S Peeper
Netherlands Cancer Institute
Career Start Year 1987
Number of shared co-authors 20
Craig L Slingluff
University of Virginia
Career Start Year 1987
Number of shared co-authors 13
Jonathan Cebon
Australia Olivia Newton-John Cancer Research Institute, La Trobe University
Career Start Year 1985
Number of shared co-authors 13
Colin R Goding
Ludwig Institute for Cancer Research, University of Oxford
Career Start Year 1983
Number of shared co-authors 14
Molly Kulesz-Martin
Oregon Health & Science University
Career Start Year 1980
Number of shared co-authors 4
Fabien Calvo
Universite de Paris-Cite
Career Start Year 1979
Number of shared co-authors 2
Evelyn Flynn
Boston Children's Hospital
Career Start Year 1978
Number of shared co-authors 1
Margaret A Tucker
National Cancer Institute
Career Start Year 1976
Number of shared co-authors 7
William A Robinson
National Centre for Asbestos Related Diseases, University of Western Australia
Career Start Year 1967
Number of shared co-authors 18

Collaborators

Gao Zhang
Co-authored papers 55
Katherine L Nathanson
Perelman School of Medicine, University of Pennsylvania, USA Abramson Cancer Center
Co-authored papers 32
Zhi Wei
Co-authored papers 28
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 25
Ashani T Weeraratna
Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine
Co-authored papers 22
Yiling Lu
Co-authored papers 21
David W Speicher
Co-authored papers 19
John Alan Diehl
Case Western Reserve University School of Medicine
Co-authored papers 17
Michael A Davies
The University of Texas MD Anderson Cancer Center
Co-authored papers 17
Andrew V Kossenkov
The Wistar Institute
Co-authored papers 13
Ze'ev Ronai
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Co-authored papers 12
Jie Zhang
Co-authored papers 11
Susan E Zabierowski
Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center
Co-authored papers 11
Jennifer A Wargo
Co-authored papers 10
Andrew E Aplin
Thomas Jefferson University
Co-authored papers 8
Chaoran Cheng
Co-authored papers 8
Barbara L Weber
Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania
Co-authored papers 7
Rolf Swoboda
Melanoma Research Center, The Wistar Institute
Co-authored papers 7
Richard A Sturm
Frazer Institute, The University of Queensland, Dermatology Research Centre
Co-authored papers 7
Reinhard Dummer
University Hospital Zurich
Co-authored papers 7
Stephan N Wagner
Co-authored papers 7
Eytan Ruppin
National Cancer Institute
Co-authored papers 6
Dirk Schadendorf
Co-authored papers 6
Ronen Marmorstein
Perelman School of Medicine, University of Pennsylvania
Co-authored papers 6
Dave S B Hoon
Saint John's Cancer Institute at Saint John's Health Center
Co-authored papers 6
Lawrence N Kwong
The University of Texas MD Anderson Cancer Center
Co-authored papers 6
Michael Detmar
Institute of Pharmaceutical Sciences, ETH Zurich
Co-authored papers 5
Marcus Bosenberg
Yale School of Medicine
Co-authored papers 5
Carsten O Daub
International Institute of Molecular and Cell Biology in Warsaw
Co-authored papers 4
Peter Zhang
Child and Family Research Institute, University of British Columbia
Co-authored papers 4
Release 1.2